Compare Crown Castle International Corp (CCI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Crown Castle International Corp trades at $73.96 (market cap $31.33B), while State Street SPDR S&P Biotech ETF trades at $159.12. The key difference: Crown Castle International Corp pays a 5.77% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Crown Castle International Corp nearer its low. Which is the better fit depends on your goals.
| CCI | XBI | |
|---|---|---|
Market Cap | $31.33B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $103.79 | $164.28 |
52-Week Low | $73.61 | $86.92 |
Enterprise Value | $53.69B | — |
Dividend Yield | 5.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $74.06, up 0.61% today, near a one-year low. The stock shows a bearish technical trend but maintains a 5.5% dividend yield. Recent Q2 2026 earnings beat AFFO estimates, with organic growth of 3.9%, though revenue declined year-over-year. The company completed its transition to a pure-play U.S. tower operator after selling its fiber business.
Outlook is mixed: analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting 29% upside. Key risks include high debt levels (debt-to-asset ratio of 77.21% in 2025) and competitive pressure in the tower REIT sector. The current valuation appears discounted relative to historical multiples, offering potential for income-focused investors.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
